iron overload in thalassaemia intermedia : reassessment of iron chelation strategies
DESCRIPTION
Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies. Ali Taher,1 Chaim Hershko2 and Maria Domenica Cappellini. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/1.jpg)
IRON OVERLOAD IN THALASSAEMIA
INTERMEDIA: REASSESSMENT OF IRON CHELATION STRATEGIES
![Page 2: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/2.jpg)
Ali Taher,1 Chaim Hershko2 and Maria Domenica Cappellini
![Page 3: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/3.jpg)
Thalassaemia intermedia (TI) is a syndrome marked by its diverse underlying genetic basis, associated with anaemia and a range of specific complications including extramedullary haematopoiesis, leg ulcers, gallstones, a hypercoagulable state and pulmonary hypertension (PHT)
![Page 4: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/4.jpg)
The clinical manifestations of TI in beta- and beta-thalassaemia/haemoglobin E patients result from three key factors:
- ineffective erythropoiesis - chronic anaemia - iron overload
![Page 5: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/5.jpg)
These life-threatening complications are observed with increasing frequency in untreated TI patients and suggest that earlier intervention aimed at preventing chronic anaemia may benefit TI patients by avoiding the late and irreversible anaemia-related complications
![Page 6: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/6.jpg)
UNDERSTANDING IRON ACCUMULATION INTHALASSAEMIA INTERMEDIA Iron is an essential element for the
functioning of a great number of proteins participating in vital reactions controlling energy production, mitochondrial respiration and DNA synthesis
![Page 7: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/7.jpg)
effective mechanisms have been developed to ensure unimpeded iron supply, facilitating iron transport and accumulation.
![Page 8: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/8.jpg)
The master regulator of iron balance in humans is hepcidin
a Increased production of hepcidin in response to excessive iron or inflammation prevents the absorption of intestinal iron and blocks the recycling of catabolic iron from the reticuloendothelial (RE) system.
![Page 9: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/9.jpg)
In iron deficiency, hepcidin production is inhibited resulting in increased intestinal iron absorption and increased release of RE iron.
In hereditary haemochromatosis, mutations interfering with hepcidin regulation result in an inability to inhibit iron absorption leading to abnormal iron accumulation throughout life.
![Page 10: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/10.jpg)
patients with TI accumulate iron primarily due to increased intestinal iron absorption
In TM and TI, basic iron regulatory mechanisms remain intact. However, the chronic anaemia and ineffective erythropoiesis associated with the thalassaemia syndromes result in abnormal iron regulation.
![Page 11: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/11.jpg)
This dysregulation is caused by two newly described inhibitors of hepcidin production:
- growth differentiation factor 15 (GDF15), secreted by erythroid precursors that are greatly expanded in thalassaemia
- and hypoxiainducible transcription factors (HIFs) that control iron homeostasis by downregulating hepcidin production in response to chronic anaemia/hypoxia.
![Page 12: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/12.jpg)
This results in depletion of macrophage iron, and may explain the relatively low levels of serum ferritin encountered in TI and underestimation of the severity of tissue siderosis.
![Page 13: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/13.jpg)
The situation in TI is similar to that seen in patients with hereditary haemochromatosis syndromes, which is characterised by impaired hepcidin production.
![Page 14: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/14.jpg)
in transfused TM patients, iron is preferentially distributed to the RE system, stimulating ferritin synthesis and its release to the circulation, resulting in high serum ferritin levels
![Page 15: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/15.jpg)
THE IMPACT OF BLOOD TRANSFUSION THERAPY normal conditions: intestinal iron
absorption is 1 mg/d, under maximal stimulation : may reach 3 or 4 mg/d, amounting to an annual
iron accumulation of approximately 1000 mg.
transfused blood contains 200 mg of iron per unit and receiving 2 - 4 units of blood per month, may result in an annual accumulation of 5000- 10 000 mg of iron.
![Page 16: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/16.jpg)
In addition, blood transfusions modify hepcidin production by altering all three factors responsible for the clinical manifestations of thalassaemia
![Page 17: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/17.jpg)
(i) by correcting anaemia, transfusion therapy will suppress ineffective erythropoiesis and the associated increase in GDF15
(ii) by correcting anaemia, blood transfusions will prevent the hypoxia responsible for increased HIF production and
hypoxia-associated suppression of hepcidin
![Page 18: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/18.jpg)
(iii) increased body iron and transferrin saturation will stimulate hepcidin production
The result will be a relative increase in hepcidin production in polytransfused TM patients countering the hepcidin-inhibitory effects of anaemia and ineffective erythropoiesis.
![Page 19: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/19.jpg)
earlier initiation of regular transfusion therapy in patients with TI may improve quality of life, particularly in patients with more severe forms of TI
![Page 20: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/20.jpg)
COMPLICATIONS OF TI THAT MAY BE RELATED TO IRON LOADING accumulation of iron in patients with TI
is an ongoing process that requires regular assessment and management. And is age related, reflecting increased iron accumulation over time, even in the absence of transfusion therapy
![Page 21: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/21.jpg)
Magnetic resonance imaging (MRI) of untransfused or
minimally transfused TI patients has shown that iron accumulation occurs primarily in the liver, which predisposes to the development of fibrosis and cirrhosis, while iron overload in cardiac tissue is generally absent
![Page 22: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/22.jpg)
while heart failure as a result of iron overload is the most common cause of death in patients with TM, cardiac problems due to myocardial siderosis are less apparent in patients with TI
![Page 23: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/23.jpg)
a study of patients with TI has shown that 5.4% had congestive heart failure, 34.5% had chronic pericardial changes, more than 50% had valvular problems and 59.1% had signs of PHT, an important cause of secondary right heart failure
![Page 24: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/24.jpg)
Indeed, PHT is present in 23–60% of TI patients but rarely evident in well-treated TM patients PHT is not only a consequence of the chronic hypoxic damage that progresses with age, but is also gnificantly correlated with iron overload
![Page 25: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/25.jpg)
NORMAL IRON EQUILIBRIUM
![Page 26: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/26.jpg)
IRON BALANCE IN THALASSAEMIA INTERMEDIA
![Page 27: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/27.jpg)
IRON BALANCE IN THALASSAEMIA MAJOR
![Page 28: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/28.jpg)
ASSESSING IRON LEVELS IN PATIENTS WITHTHALASSAEMIA INTERMEDIA principal methods of determining body
iron levels are measurement of serum ferritin and assessment of liver iron concentration (LIC) from biopsy material.
Non-invasive approaches to determine LIC are increasingly used as an alternative to biopsy, and R2· (MRI) is a validated and standardised method that is now widely available
![Page 29: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/29.jpg)
Biomagnetic liver susceptometry, or SQUID (superconducting quantum interference device), is an elegant non-invasive method for measuring LIC but is available only at a limited number of centres worldwide
Non-transferrin bound iron (NTBI) or its labile plasma iron (LPI) component, is the product of severe iron overload and is a marker of increased risk of siderotic myocardial disease in TM.
![Page 30: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/30.jpg)
A significant correlation between serum ferritin and LIC has been established in regularly transfused patients with TM
![Page 31: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/31.jpg)
IRON CHELATION THERAPY There are currently no clear guidelines
for the management of iron overload in patients with TI.
use of one of the orally effective iron chelators would be optimal for TI.
it may be expected that achieving a negative iron balance in thalassaemia intermedia will be relatively simple.
![Page 32: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/32.jpg)
Data on the use of the deferoxamine (DFO) in patients with TI are limited, and our knowledge and understanding of the efficacy
and application of DFO relies mainly on the extensive experience gained from studies of the TM population.
![Page 33: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/33.jpg)
Observations during the study indicated that patients may have positive iron balance from the age of 5 years, even in the absence of transfusions, and the authors recommended that iron chelation therapy be initiated in patients over this age
![Page 34: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/34.jpg)
Data reporting the use of the first oral iron chelator, deferiprone, in patients with TI are also limited.
![Page 35: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/35.jpg)
In the clinical trial, deferiprone was studied in nine intermittently transfused TI patients, demonstrating significant reductions in mean serum ferritin, hepatic iron, red-cell membrane iron and serum nontransferrin-bound iron level
![Page 36: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/36.jpg)
Adverse events in this study were mild and included gastrointestinal symptoms in six patients and arthralgia in one, none requiring withdrawal of treatment.
deferiprone requires three-times-daily dosing to provide adequate chelator coverage, but studies have shown that levels of LPI increase between doses
![Page 37: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/37.jpg)
Deferasirox (Exjade, Novartis Pharma AG, Basel, Switzerland) is the most recent addition to the iron chelator options.
once-daily oral dosing, it can provide 24-h chelation coverage
![Page 38: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/38.jpg)
RECOMMENDATIONS FOR IRON CHELATION THERAPY IN PATIENTS WITH THALASSAEMIA INTERMEDIA
the recommended and preferred method of disease specific guidance for the management of patients with TI is direct assessment of LIC by biopsy, or preferably by noninvasive imaging methods .
Chelation therapy should be initiated when LIC exceeds 7 mg Fe/g dry weight .
![Page 39: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/39.jpg)
Where LIC measurement is not possible, threshold serum ferritin values of 400 - 500 lg/l (which have been shown to correlate with LIC levels of approximately 7 mg/g;
repeated serum ferritin measurements is appropriate for intra-individual monitoring of chelation efficiency on a regular basis.
![Page 40: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/40.jpg)
an association between iron loading evident form longitudinal elevations in serum ferritin level and worsening of hepatic fibrosis in nonchelated patients with thalassemia intermedia has been recently confirmed
reports documenting the occurrence of hepatocellular carcinoma in hepatitis negative
patients with thalassemia intermedia and iron overload continue to emerge
![Page 41: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/41.jpg)
Each 1mg Fe/g dw increase in LIC was significantly associated with an increased risk of thrombosis, pulmonary hypertension, hypothyroidism, hypogonadism, and osteoporosis.
LIC values of at least 6–7mg Fe/g dw discriminated patients who developed morbidity from those who did not
![Page 42: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/42.jpg)
Serum ferritin level of more than 800 ng/ml was the threshold after which all patients became at risk of developing morbidity
An association between iron overload and renal tubular dysfunction as evident from proteinuria has also been recently reported in thalassemia intermedia patients
![Page 43: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/43.jpg)
a high prevalence of silent brain infarction, large cerebral vessel disease, and decreased neuronal function primarily in the temporal and parietal lobes in splenectomized adults with thalassemia intermedia.
A significant association between the occurrence of large-vessel cerebrovascular disease and high NTBI levels
![Page 44: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/44.jpg)
decreased neuronal function was observed more frequently in patients with LIC more than 15mg Fe/g dw .
relationship between iron overload and hepatic or endocrine disease in thalassemia intermedia patients
![Page 45: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/45.jpg)
The presence of NTBI in the sera of thalassemia intermedia patients can cause oxidative vessel injury and endothelial activation
iron overload could lead to hepatic disease and subsequent alterations in coagulation factor levels, thus worsening the hypercoagulable state implicated in thalassemia intermedia
![Page 46: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/46.jpg)
reduction of iron overload affects erythropoietic capacity and leads to improvements in hemoglobin level and red cell survival
![Page 47: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/47.jpg)
IRON OVERLOAD ASSESSMENT INTHALASSEMIA INTERMEDIA PATIENTS Direct assessment of LIC by biopsy or
MRI is recommended (gold standard).
assessment of LIC need not start before patients reach 10 years of age, especially given that the prevalence of iron-related morbidities in patients less than 10 years is low
![Page 48: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/48.jpg)
Measurements can be done at 1 or even 2-year intervals
![Page 49: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/49.jpg)
MANAGEMENT OF IRON OVERLOAD INTHALASSEMIA INTERMEDIA PATIENTS Oral chelator deferasirox ,significant
reduction of LIC compared with placebo following 12 months of therapy in patients aged at least 10 years with a baseline LIC at least 5mg Fe/g dw. LIC decreased by a mean of 2.330.70 and 4.180.69mg Fe/g dw in patients receiving starting doses of 5 and 10 mg/kg per day, respectively.
![Page 50: Iron overload in thalassaemia intermedia : reassessment of iron chelation strategies](https://reader036.vdocument.in/reader036/viewer/2022062323/568166d5550346895ddaeb02/html5/thumbnails/50.jpg)
most common drug-related adverse events being nausea (6.6%), rash (4.8%), and diarrhea (3.6%)
initiation: serum ferritin of 800 ng/ml corresponds to a LIC of 5mg Fe/g dw; suspension: serum ferritin of 300 ng/ml corresponds to a LIC of 3mg Fe/g dw)